A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency

Vascular Diseases Center, University of Ferrara, Ferrara, Italy.
Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter (Impact Factor: 2.98). 12/2009; 50(6):1348-58.e1-3. DOI: 10.1016/j.jvs.2009.07.096
Source: PubMed

ABSTRACT Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by combined stenoses of the principal pathways of extracranial venous drainage, including the internal jugular veins (IJVs) and the azygous (AZY) vein, with development of collateral circles and insufficient drainage shown by increased mean transit time in cerebral magnetic resonance (MR) perfusion studies. CCSVI is strongly associated with multiple sclerosis (MS). This study evaluated the safety of CCSVI endovascular treatment and its influence on the clinical outcome of the associated MS.
Sixty-five consecutive patients with CCSVI, subdivided by MS clinical course into 35 with relapsing remitting (RR), 20 with secondary progressive (SP), and 10 with primary progressive (PP) MS, underwent percutaneous transluminal angioplasty (PTA). Mean follow-up was 18 months. Vascular outcome measures were postoperative complications, venous pressure, and patency rate. Neurologic outcome measures were cognitive and motor function assessment, rate of MS relapse, rate of MR active positive-enhanced gadolinium MS lesions (Gad+), and quality of life (QOL) MS questionnaire.
Outpatient endovascular treatment of CCSVI was feasible, with a minor and negligible complication rate. Postoperative venous pressure was significantly lower in the IJVs and AZY (P < .001). The risk of restenosis was higher in the IJVs compared with the AZY (patency rate: IJV, 53%; AZY, 96%; odds ratio, 16; 95% confidence interval, 3.5-72.5; P < .0001). CCSVI endovascular treatment significantly improved MS clinical outcome measures, especially in the RR group: the rate of relapse-free patients changed from 27% to 50% postoperatively (P < .001) and of MR Gad+ lesions from 50% to 12% (P < .0001). The Multiple Sclerosis Functional Composite at 1 year improved significantly in RR patients (P < .008) but not in PP or SP. Physical QOL improved significantly in RR (P < .01) and in PP patients (P < .03), with a positive trend in SP (P < .08). Mental QOL showed significant improvement in RR (P < .003) and in PP (P < .01), but not in SP.
PTA of venous strictures in patients with CCSVI is safe, and especially in patients with RR, the clinical course positively influenced clinical and QOL parameters of the associated MS compared with the preoperative assessment. Restenosis rates are elevated in the IJVs but very promising in the AZY, suggesting the need to improve endovascular techniques in the former. The results of this pilot study warrant a subsequent randomized control study.

  • Source
    01/2015; 5(1). DOI:10.1002/brb3.308
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Article Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system with an unknown etiol-ogy that affects more than two million individuals worldwide (Multiple Sclerosis International Federation, 2013). Research on the natural history of MS paints a picture of a disease with different trajectories (Debouverie, Pittion-Vouyovitch, Louis, & Guillemin, 2008). However, 80% of MS patients have a walking impairment within 10 to 15 years of disease onset (Souza et al., 2010), and 50% of these patients require ambulatory assistance in another 5 years (i.e., within 15–20 years of disease onset), even though disease progression might be slowing down (Tremlett, Zhao, Rieckmann, & Hutchinson, 2010). The risk of all-cause mortality in MS patients is two to three times that in the general population (Kingwell et al., 2012). The global economic and human costs of MS are high. In the United States alone, the total annual expenditures attributable to MS are estimated at US$billion (National Multiple Sclerosis Society [NMSS], 2013a). Disease-modifying therapies diminish the frequency and severity of relapses, decelerate the progression of disability, decrease the number of brain lesions, and enhance the qual-ity of life of MS patients (Goodin et al., 2002). However, there is no cure for MS (NMSS, 2013b). Consequently, MS patients often resort to complementary and alternative medi-cine (CAM) in the hope of obtaining an effective treatment (Olsen, 2009). In fact, despite the lack of conclusive empiri-cal evidence supporting the usefulness of several CAM modalities for the treatment of MS (Bowling, 2011; Namaka et al., 2008), this patient population has a widespread pattern of CAM use (Stoll, Nieves, Tabby, & Schwartzman, 2012). In the past, the MS community at large has eagerly tried con-troversial and unsubstantiated remedies, such as bee-venom therapy (Wesselius et al., 2005). In 2009, the news of a novel theory on the nature of MS, which was proposed by the Italian physician and researcher Paolo Zamboni, captured the attention of international media outlets. Zamboni reported that MS might be the result of
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cause of multiple sclerosis is believed to involve environmental exposure and genetic susceptibility. We aimed to summarise the environmental risk factors that have been studied in relation to onset of multiple sclerosis, assess whether there is evidence for diverse biases in this literature, and identify risk factors without evidence of biases. We searched PubMed from inception to Nov 22, 2014, to identify systematic reviews and meta-analyses of observational studies that examined associations between environmental factors and multiple sclerosis. For each meta-analysis we estimated the summary effect size by use of random-effects and fixed-effects models, the 95% CI, and the 95% prediction interval. We estimated the between-study heterogeneity expressed by I(2) (defined as large for I(2)≥50%), evidence of small-study effects (ie, large studies had significantly more conservative results than smaller studies), and evidence of excess significance bias (ie, more studies than expected with significant results). Overall, 44 unique meta-analyses including 416 primary studies of different risk factors and multiple sclerosis were examined, covering a wide range of risk factors: vaccinations, comorbid diseases, surgeries, traumatic events and accidents, exposure to environmental agents, and biochemical, infectious, and musculoskeletal biomarkers. 23 of 44 meta-analyses had results that were significant at p values less than 0·05 and 11 at p values less than 0·001 under the random-effects model. Only three of the 11 significant meta-analyses (p<0·001) included more than 1000 cases, had 95% prediction intervals excluding the null value, and were not suggestive of large heterogeneity (I(2)<50%), small-study effects (p for Egger's test >0·10), or excess significance (p>0·05). These were IgG seropositivity to Epstein-Barr virus nuclear antigen (EBNA) (random effects odds ratio [OR] 4·46, 95% CI 3·26-6·09; p for effect size=1·5 × 10(-19); I(2)=43%), infectious mononucleosis (2·17, 1·97-2·39; p=3·1 × 10(-50); I(2)=0%), and smoking (1·52, 1·39-1·66; p=1·7 × 10(-18;)I(2)=0%). Many studies on environmental factors associated with multiple sclerosis have caveats casting doubts on their validity. Data from more and better-designed studies are needed to establish robust evidence. A biomarker of Epstein-Barr virus (anti-EBNA IgG seropositivity), infectious mononucleosis, and smoking showed the strongest consistent evidence of an association. None. Copyright © 2015 Elsevier Ltd. All rights reserved.
    The Lancet Neurology 02/2015; 14(3). DOI:10.1016/S1474-4422(14)70267-4 · 21.82 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014